2013
Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial
Dizon J, Brener S, Maehara A, Witzenbichler B, Biviano A, Godlewski J, Parise H, Dambrink J, Mehran R, Gibson C, Stone G. Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 78-83. PMID: 24562806, PMCID: PMC3932776, DOI: 10.1177/2048872613508658.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAnterior Wall Myocardial InfarctionAntibodies, MonoclonalCoronary AngiographyElectrocardiographyFemaleHeart VentriclesHumansImmunoglobulin Fab FragmentsInfusions, IntravenousMagnetic Resonance Imaging, CineMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexTreatment OutcomeConceptsST-segment elevation myocardial infarctionST-segment resolutionST-segment elevationAnterior ST-segment elevation myocardial infarctionResidual ST-segment elevationDays post interventionINFUSE-AMI trialMin post interventionInfarct sizeMicrovascular obstructionPost interventionInfarct massBaseline ST-segment elevationPrimary percutaneous coronary interventionSimple ECG parametersUltimate infarct sizeElevation myocardial infarctionPercutaneous coronary interventionInfarct-related leadsTotal LV massQ wave changesSignificant Q wavesECG methodSingle leadBolus abciximabImpact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction
MINDRESCU C, BRENER S, GUERCHICOFF A, FAHY M, PARISE H, MEHRAN R, STONE G. Impact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction. Journal Of Interventional Cardiology 2013, 26: 319-324. PMID: 23795656, DOI: 10.1111/joic.12038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionTarget vessel revascularizationPercutaneous coronary interventionPrimary percutaneous coronary interventionElevation myocardial infarctionMyocardial infarctionCoronary interventionStent thrombosisAcute Myocardial Infarction trialMyocardial Infarction trialOutcomes of patientsRate of revascularizationAngiographic Follow-upSAF groupRate of deathHarmonizing OutcomesVessel revascularizationCerebral eventsMI ratesFollow-upPatientsRevascularizationInfarctionComposite rateDeathImpact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery
Wöhrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, Grines C, McAndrew T, Parise H, Sergie Z, Mehran R, Stone G. Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery. The American Journal Of Cardiology 2013, 112: 753-760. PMID: 23746479, DOI: 10.1016/j.amjcard.2013.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, PhytogenicAntithrombinsCoronary AngiographyCoronary VesselsDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansMaleMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPercutaneous Coronary InterventionProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionPaclitaxel-eluting stentingImpact of bivalirudinTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationCoronary interventionCardiac deathPrimary PCIGlycoprotein IIb/IIIa inhibitorsIschemia-driven target vessel revascularizationIIb/IIIa inhibitorsLeft anterior descending (LAD) arteryHORIZONS-AMI trialMajor bleeding eventsUse of bivalirudinAnterior descending (LAD) arteryElevation myocardial infarctionBare-metal stentingSignificant lower rateLower ratesBleeding eventsCardiovascular eventsRevascularization ratesInfarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial
Brener S, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink J, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson C, Stone G. Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. American Heart Journal 2013, 166: 64-70. PMID: 23816023, DOI: 10.1016/j.ahj.2013.03.029.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAntibodies, MonoclonalCardiac CatheterizationCoronary AngiographyCoronary StenosisCoronary VesselsElectrocardiographyFemaleHumansImmunoglobulin Fab FragmentsInjections, Intra-ArterialMagnetic Resonance Imaging, CineMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexSurvival RateThrombectomyTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionInfarct sizeMyocardial infarctionAnterior ST-segment elevation myocardial infarctionMyocardial blush grade 2/3Myocardial infarction flow 3Primary percutaneous coronary interventionINFUSE-AMI trialMyocardial Infarction trialPrimary end pointST-segment resolutionPercutaneous coronary interventionSeptal perforator branchExtent of myocardiumEffect of ICSBivalirudin anticoagulationBolus abciximabFinal ThrombolysisIntracoronary abciximabKillip classLAD infarctsReperfusion therapyArtery occlusionCoronary intervention
2012
Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Fiocca L, Guagliumi G, Rossini R, Parise H, Musumeci G, Sirbu V, Lortkipanidze N, Yu J, Mihalcsik L, Vassileva A, Valsecchi O, Gavazzi A, Mehran R, Stone G. Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. The American Journal Of Cardiology 2012, 111: 196-201. PMID: 23111141, DOI: 10.1016/j.amjcard.2012.09.019.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionAcute Myocardial Infarction trialKillip class IIIMyocardial Infarction trialOutcomes of patientsElevation myocardial infarctionHarmonizing OutcomesMyocardial infarctionMyocardial Infarction flow grade 3Major adverse cardiovascular eventsNet adverse clinical eventsClass IIIHORIZONS-AMI trialTrial eligible groupAdverse cardiovascular eventsHigh-risk featuresAdverse clinical eventsVentricular ejection fractionBroad inclusion criteriaFinal ThrombolysisMajor bleedingCardiovascular eventsCause mortalityAdverse eventsBaseline characteristics
2011
Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey T, Fahy M, Parise H, Stone G. Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 760-768. PMID: 21777884, DOI: 10.1016/j.jcin.2011.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyDiabetes MellitusDose-Response Relationship, DrugDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionPeptide FragmentsProspective StudiesRecombinant ProteinsStentsSurvival RateTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionHORIZONS-AMI trialDiabetes mellitusDiabetic patientsMyocardial infarctionPrimary PCIMajor adverse cardiac eventsIIb/IIIa inhibitorsEffectiveness of bivalirudinEfficacy of bivalirudinAdverse cardiac eventsAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionAcute myocardial infarctionMajor bleedingCardiac mortalityCoronary syndromeAnticoagulant therapyCardiac eventsCoronary interventionCardiac deathUnfractionated heparinHeparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarction
2004
Mitral annular calcification is a predictor for incident atrial fibrillation
Fox C, Parise H, Vasan R, Levy D, O’Donnell C, D’Agostino R, Plehn J, Benjamin E. Mitral annular calcification is a predictor for incident atrial fibrillation. Atherosclerosis 2004, 173: 291-294. PMID: 15064104, DOI: 10.1016/j.atherosclerosis.2003.12.018.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionAgedAged, 80 and overAtrial FibrillationCalcinosisCohort StudiesComorbidityEchocardiography, DopplerElectrocardiographyFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedMitral Valve StenosisProbabilityProportional Hazards ModelsRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex DistributionConceptsMitral annular calcificationIncident atrial fibrillationAtrial fibrillationAnnular calcificationAdverse cardiovascular disease outcomesSex-adjusted incidence ratesRisk of AFLeft atrial sizeMultivariable-adjusted analysesCardiac valvular calcificationCardiovascular disease outcomesCommunity-based cohortM-mode echocardiographyProportional hazards modelLong-term riskFramingham Heart StudyIncident AFHazard ratioAtrial enlargementAtrial sizeEchocardiographic assessmentValvular calcificationOriginal cohortProspective dataIncidence rate